
Aleix Prat
Oncology Department OncologistAbout me
Graduated in Medicine at University of Barcelona (UB) in 2003. In 2008 he obtained a specialty in Medical Oncology, in 2013 he obtained the Extraordinary Doctorate Award from the Autonomous University of Barcelona. Currently the Director Institut of Oncology at Hospital Clínic Barcelona, Professor of Medicine (Medical Oncology) at the UB and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS. Furthermore, he is the Head of the Breast Cancer programme at IOB- Quiron salud as well as CEO and co-founder of the spin-off called Reveal Genomics, where has been developed the HER2DX® diagnostic test just recognized by TIME as one of the best inventions of 2022.
Featured publications
-
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
Authors:Reference: Annals Of Oncology 2025. -
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies
Authors:Reference: Ebiomedicine 2024. -
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Authors:Reference: Annals Of Oncology 2023. -
Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study
Authors:Reference: Annals Of Oncology 2023. -
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Authors:Reference: Nature Communications 2023. -
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Authors:Reference: Ebiomedicine 2022. -
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Authors:Reference: Journal Of Clinical Oncology 2021. -
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Authors:Reference: Lancet Oncology 2020. -
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Authors:Reference: Lancet Oncology 2020. -
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial
Authors:Reference: Lancet Oncology 2017.
Featured Projects
-
A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology
Principal investigator: Jordi Rimola Gibert, Aleix Prat AparicioFunder: European CommissionCode: CE_H2020_SC1_20_1s13Duration: 01/10/2020 - 30/09/2024 -
RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.
Principal investigator: Aleix Prat AparicioFunder: European CommissionCode: H2020-SC1-BHC-02-2019 / 847912-2Duration: 01/01/2020 - 31/12/2024 -
Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer
Principal investigator: Aleix Prat AparicioFunder: Asociación Española Contra el CáncerCode: GCAEC19010PRATDuration: 01/12/2019 - 30/11/2024 -
Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer.
Principal investigator: Aleix Prat AparicioFunder: Fundació La Marató de TV3Code: 201935-30Duration: 30/07/2020 - 31/12/2023 -
Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama.
Principal investigator: Aleix Prat AparicioFunder: I Premio M. Chiara GiorgettiCode: CMM_CHIARAG19_001Duration: 01/02/2020 - 31/07/2021